Roche’s Fuchs Says mRNA Could Change Landscape of Cancer Therapy

Messenger RNA vaccines have great promise as potential cancer treatments, Roche Holding AG’s cancer and hematology chief said, suggesting the technology’s usefulness may go well beyond infectious diseases.

“It’s an exciting technology,” Charles Fuchs, Roche’s global head of oncology and hematology drug development, said in an interview. “It has certainly borne fruit in terms of revolutionizing vaccines to viruses, and I think it has the potential to change the landscape for cancer immunotherapy.”

Roche is working with BioNTech SE, which produced a Covid-19 shot with Pfizer Inc., on a personalized mRNA cancer vaccine that seeks to ...